Heather A. Wakelee

2004–2025 年に発表

162
論文数
28,672
被引用数
85
h 指数
154
i10 指数

被引用数

Heather A. Wakelee の年別被引用数1971 年: 被引用 1 件1994 年: 被引用 1 件2004 年: 被引用 4 件2005 年: 被引用 14 件2006 年: 被引用 10 件2007 年: 被引用 14 件2008 年: 被引用 27 件2009 年: 被引用 37 件2010 年: 被引用 58 件2011 年: 被引用 52 件2012 年: 被引用 69 件2013 年: 被引用 53 件2014 年: 被引用 70 件2015 年: 被引用 144 件2016 年: 被引用 232 件2017 年: 被引用 308 件2018 年: 被引用 339 件2019 年: 被引用 898 件2020 年: 被引用 1,400 件2021 年: 被引用 1,587 件2022 年: 被引用 1,378 件2023 年: 被引用 1,279 件2024 年: 被引用 1,873 件2025 年: 被引用 1,044 件2026 年: 被引用 24 件1972〜1993 年は被引用が無いため表示していません1995〜2003 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,542 件、この内訳の 24.8%中国: 引用元論文 2,204 件、この内訳の 15.4%イタリア: 引用元論文 851 件、この内訳の 6%イギリス: 引用元論文 696 件、この内訳の 4.9%フランス: 引用元論文 621 件、この内訳の 4.3%ドイツ: 引用元論文 548 件、この内訳の 3.8%日本: 引用元論文 515 件、この内訳の 3.6%スペイン: 引用元論文 507 件、この内訳の 3.6%カナダ: 引用元論文 462 件、この内訳の 3.2%オランダ: 引用元論文 378 件、この内訳の 2.6%韓国: 引用元論文 352 件、この内訳の 2.5%スイス: 引用元論文 333 件、この内訳の 2.3%
0%24.8%その他 23%

分野

  • Medicine60%
  • Biochemistry, Genetics and Molecular Biology30.7%
  • Immunology and Microbiology5.3%
  • Engineering1.2%
  • Computer Science0.5%
  • Chemistry0.4%
  • その他1.9%

トピック

  • Lung Cancer Treatments and Mutations12.7%
  • Cancer Genomics and Diagnostics9.4%
  • Cancer Immunotherapy and Biomarkers6.6%
  • Lung Cancer Research Studies5.6%
  • Lung Cancer Diagnosis and Treatment5.3%
  • Cancer Cells and Metastasis1.8%
  • その他58.6%

共著者

全論文

検索で開く
  1. Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer

    著者: , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2023 被引用: 1,030

  2. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , - The Lancet 2021 被引用: 1,479

  3. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Robert D. Schouten, Heather A. Wakelee, D. Ross Camidge, Gérard Zalcman, Silvia Novello, Sai‐Hong Ignatius Ou, Julie Milia, Oliver Gautschi - Annals of Oncology 2019 被引用: 1,361

  4. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage

    著者: , , , , , , , , , , , , , - Nature Medicine 2014 被引用: 2,252

  5. Integrating genomic features for non-invasive early lung cancer detection

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Robert Tibshirani, Sanjiv S. Gambhir, Gerald J. Berry, Kristin C. Jensen, Robert B. West, Joel W. Neal, Heather A. Wakelee, Billy W. Loo, Christian A. Kunder, Ann N. Leung, Natalie S. Lui, Mark F. Berry, Joseph B. Shrager, Viswam S. Nair, Daniel A. Haber, Lecia V. Sequist, Ash A. Alizadeh, Maximilian Diehn - Nature 2020 被引用: 703

  6. Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - Cancer Discovery 2017 被引用: 1,078

  7. Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Thoracic Oncology 2021 被引用: 645

  8. Integrated digital error suppression for improved detection of circulating tumor DNA

    著者: , , , , , , , , , , , , , , , , , , , - Nature Biotechnology 2016 被引用: 1,144

  9. First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2019 被引用: 590

  10. Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jing Wang, Blerina Resuli, Lorenza Landi, Shu-Chi Tseng, Mizuki Nishino, Subba R. Digumarthy, Waree Rinsurongkawong, Vadeerat Rinsurongkawong, Ara A. Vaporciyan, George R. Blumenschein, Jianjun Zhang, Dwight H. Owen, Collin M. Blakely, Giannis Mountzios, Catherine A. Shu, Christine M. Bestvina, Marina Chiara Garassino, Kristen A. Marrone, Jhanelle E. Gray, Sandip Pravin Patel, Amy L. Cummings, Heather A. Wakelee, Juergen Wolf, Giorgio V. Scagliotti, Federico Cappuzzo, Fabrice Barlési, Pradnya D. Patil, Leylah Drusbosky, Don L. Gibbons, Funda Meric‐Bernstam, J. Jack Lee, John V. Heymach, David S. Hong, Rebecca S. Heist, Mark M. Awad, Ferdinandos Skoulidis - Cancer Discovery 2023 被引用: 181

  11. EGFR -Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes

    著者: , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2018 被引用: 471

  12. Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Cancer 2020 被引用: 370

  13. Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor–Induced Myocarditis

    著者: , , , , , , , , , , , , , , , , - Circulation 2022 被引用: 174

  14. Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ash A. Alizadeh, Maximilian Diehn - Cell 2020 被引用: 369

  15. Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase−Positive Non–Small Cell Lung Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , - JAMA Oncology 2021 被引用: 245

  16. Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Amy Spelman, Yasir Y. Elamin, Marcelo V. Negrão, Ferdinandos Skoulidis, Carl M. Gay, Tina Cascone, Mara B. Antonoff, Boris Sepesi, Jeff Lewis, Ignacio I. Wistuba, John D. Hazle, Caroline Chung, David A. Jaffray, Don L. Gibbons, Ara A. Vaporciyan, J Jack Lee, John V. Heymach, Jianjun Zhang, Jia Wu - The Lancet Digital Health 2023 被引用: 109

  17. Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC

    著者: , , , , , , , , , , , , , , , , , , , , , , - Journal of Thoracic Oncology 2018 被引用: 662

  18. LBA56 Overall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC)

    著者: , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2023 被引用: 75

  19. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients

    著者: , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2016 被引用: 659

  20. Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jie Bai, Paul Begin, Aleksandr Belonogov, Henri Berard, Radu Berceanu-Ion, Reyes Bernabe Caro, Igor Bondarenko, Reiner Bonnet, Joaquim Bosch Barrera, Carlos Brocca, Maciej Bryl, Alessandra Bulotta, Olivier Bylicki, Antonio Calles Blanco, Enric Carcereny, Leticia Carvalho, Cristina Cebotaru, Jamie Chaft, Veena Charu, Fabio Chaves, Jun Chen, Ke-Neng Chen, Haiquan Chen, Qixun Chen, Kevin Chen, Chi-Lu Chiang, Chao-Hua Chiu, Saulius Cicenas, Elena Ciubotaru, Tudor Ciuleanu, Ioana Ciurescu, Patrick Cobb, Corlia Coetzee, Dearbhaile Collins, Diego Cortinovis, Kimberly Costas, Dan Costin, Eduardo Henrique Cronemberger, Raymund Cuevo, Sinead Cuffe, Pedro Rafael Martins De Marchi, Tadeu de Paiva Junior, Angelo Delmonte, Ingel Demedts, Koenraad Deschepper, Josiane Dias, Christophe Dooms, Boris Duchemann, Carolina Dutra, Herbert Duvivier, Ekkehard Eigendorff, Vinicius Ernani, Martin Faehling, Luiza Faria, Alexander Fedenko, Hiran Fernando, Roberto Ferrara, Vittorio Ferrari, Gene Finley, Peter Fix, Marcos Flores, Samuel Fourie, Fabio Franke, Klaus-Peter Frohling, Muhammad Furqan, Cristian Gal, Robert Galamaga, Doina Ganea, Apar Kishor Ganti, Shugeng Gao ほか 176 名 - The Lancet 2024 被引用: 243

  21. Myocarditis Surveillance With High-Sensitivity Troponin I During Cancer Treatment With Immune Checkpoint Inhibitors

    著者: , , , , , , , , , , , - JACC CardioOncology 2021 被引用: 118

  22. KEAP1/NFE2L2 Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase Inhibition

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Maximilian Diehn - Cancer Discovery 2020 被引用: 173

  23. Global analysis of shared T cell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Steven A. Feldman, Maximilian Diehn, Irving L. Weissman, Jianjun Zhang, Ignacio I. Wistuba, P. Andrew Futreal, John V. Heymach, K. Christopher García, Crystal L. Mackall, Mark M. Davis - Immunity 2021 被引用: 136

  24. Neoadjuvant and Adjuvant Treatments for Early Stage Resectable NSCLC: Consensus Recommendations From the International Association for the Study of Lung Cancer

    著者: , , , , , , , , , , , , , , , , , , , , - Journal of Thoracic Oncology 2024 被引用: 129